関連する実験動画
Updated: Mar 5, 2026

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
96.0K
PGC-1αの選択的化学阻害 グルコネオゲン活性 2型糖尿病を改善する
Kfir Sharabi1, Hua Lin2, Clint D J Tavares1
1Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.
Cell
|March 25, 2017
まとめ
研究者らは,PGC-1αアセチル化を標的とした小分子SR-18292を特定し,グルコースの産生を減少させた. この新しいアプローチは,グルコースホメオスタシスとインスリン感受性を改善することによって,タイプ2型糖尿病 (T2D) の治療に希望を示しています.
科学分野:
- 代謝疾患
- 分子生物学
- 薬物の発見
背景:
- 2型糖尿病 (T2D) は世界的な流行病であり,新しい治療戦略が必要です.
- 肝臓のグルコース生成抑制 (HGP) は,糖尿病治療の有効なアプローチです.
- PGC- 1αアセチル化は肝臓のグルコネオゲネシスの阻害剤として知られています.
研究 の 目的:
- T2D治療のためのPGC-1αアセチル化を強化する小分子を特定する.
- 肝臓におけるPGC-1αアセチレーションを標的とした治療の可能性を調査する.
主な方法:
- 細胞におけるPGC-1αアセチル化を測定するための高通量スクリーニングプラットフォームを開発した.
- PGC-1αアセチル化を増加させ,グルコーネオゲン遺伝子を抑制し,肝細胞からのグルコース出力を減少させる小分子が特定されました.
- T2DのマウスモデルでSR-18292を選択してテストしました.
主要な成果:
- SR-18292はPGC- 1αアセチル化を増加させ,グルコネオゲン遺伝子の発現を抑制し,肝細胞におけるグルコース生成を減少させた.
- T2Dマウスモデルでは,SR-18292の治療により血糖値が低下した.
- SR-18292は肝臓のインスリン感受性とグルコースホメオスタシスを有意に改善しました.
結論:
- PGC- 1αアセチル化をターゲットにすることは,2型糖尿病の新たな治療戦略です.
- SR-18292は臨床前モデルで有効性を示し,T2D薬としての可能性を示唆しています.
- PGC-1αの調節を理解することで,グルコース代謝と糖尿病治療の洞察が得られます.
関連する概念動画
Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Dipeptidyl Peptidase 4 Inhibitors
814
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
814
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
701
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
701
Oral Hypoglycemic Agents: Biguanides and Glitazones
755
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
755
GPCRs Regulate Adenylyl Cylase Activity
7.9K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.9K
Diabetes Mellitus: Type 2 and Gestational
5.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.2K

